Clinical Research

Reversal of aplastic anaemia secondary to systemic lupus erythematosus by high-dose intravenous cyclophosphamide

Br Med J (Clin Res Ed) 1982; 285 doi: https://doi.org/10.1136/bmj.285.6344.769 (Published 18 September 1982) Cite this as: Br Med J (Clin Res Ed) 1982;285:769
  1. M J Walport,
  2. W N Hubbard,
  3. G R V Hughes

    Abstract

    Aplastic anaemia is rare as a primary feature of systemic lupus erythematosus and is more commonly a complication of treatment with cytotoxic drugs. Three years after starting treatment for systemic lupus erythematosus a 22-year-old woman developed bone-marrow depression. Azathioprine was thought to be responsible and was withdrawn. The aplastic anaemia worsened despite treatment with prednisolone. In view of clinical and serological evidence of lupus disease activity the patient was given high-dose intravenous cyclophosphamide and the aplastic anaemia responded in a sustained manner.

    In such cases of continued disease activity high-dose immunosuppressive agents may prove effective.

    Sign in

    Log in through your institution

    Subscribe